1. Home
  2. WVE vs NHC Comparison

WVE vs NHC Comparison

Compare WVE & NHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WVE
  • NHC
  • Stock Information
  • Founded
  • WVE 2012
  • NHC 1971
  • Country
  • WVE Singapore
  • NHC United States
  • Employees
  • WVE N/A
  • NHC N/A
  • Industry
  • WVE Biotechnology: Pharmaceutical Preparations
  • NHC Hospital/Nursing Management
  • Sector
  • WVE Health Care
  • NHC Health Care
  • Exchange
  • WVE Nasdaq
  • NHC Nasdaq
  • Market Cap
  • WVE 1.8B
  • NHC 1.6B
  • IPO Year
  • WVE 2015
  • NHC N/A
  • Fundamental
  • Price
  • WVE $11.13
  • NHC $93.48
  • Analyst Decision
  • WVE Strong Buy
  • NHC
  • Analyst Count
  • WVE 10
  • NHC 0
  • Target Price
  • WVE $21.60
  • NHC N/A
  • AVG Volume (30 Days)
  • WVE 734.1K
  • NHC 52.3K
  • Earning Date
  • WVE 03-05-2025
  • NHC 02-28-2025
  • Dividend Yield
  • WVE N/A
  • NHC 2.60%
  • EPS Growth
  • WVE N/A
  • NHC 174.32
  • EPS
  • WVE N/A
  • NHC 7.98
  • Revenue
  • WVE $53,610,000.00
  • NHC $1,223,271,000.00
  • Revenue This Year
  • WVE N/A
  • NHC N/A
  • Revenue Next Year
  • WVE $48.58
  • NHC N/A
  • P/E Ratio
  • WVE N/A
  • NHC $12.07
  • Revenue Growth
  • WVE N/A
  • NHC 10.74
  • 52 Week Low
  • WVE $4.01
  • NHC $87.03
  • 52 Week High
  • WVE $16.74
  • NHC $138.49
  • Technical
  • Relative Strength Index (RSI)
  • WVE 44.53
  • NHC 32.27
  • Support Level
  • WVE $10.79
  • NHC $99.44
  • Resistance Level
  • WVE $11.78
  • NHC $104.54
  • Average True Range (ATR)
  • WVE 0.69
  • NHC 2.52
  • MACD
  • WVE 0.05
  • NHC -0.18
  • Stochastic Oscillator
  • WVE 43.95
  • NHC 3.19

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About NHC National HealthCare Corporation

National Healthcare Corp Provides long-term care facilities. Its principal business includes the operation of skilled nursing facilities, assisted living facilities, independent living facilities, and home care programs. The company's activities include providing sub-acute and post-acute skilled nursing care, intermediate nursing care, rehabilitative care, memory and Alzheimer's care, senior living services, and home health care services. In addition, the company also provides management services, accounting, and financial services, as well as insurance services to third-party operators of healthcare facilities. Its reportable segments include Inpatient services, and Home care hospice services. Generating, a majority of its revenue from Inpatient services.

Share on Social Networks: